Does sex affect the efficacy, safety, and quality of life outcomes for patients using angiotensin receptor neprilysin inhibitor, soluble guanylate cyclase stimulators, and cardiac myosin activators in heart failure? a systematic review (2025)
- Authors:
- Autor USP: AGUIAR, PATRICIA MELO - FCF
- Unidade: FCF
- DOI: 10.1016/j.hlc.2025.04.082
- Subjects: INSUFICIÊNCIA CARDÍACA; MIOSINA
- Language: Inglês
- Imprenta:
- Source:
- Título: Heart, Lung and Circulation
- ISSN: 1443-9506
- Volume/Número/Paginação/Ano: v. 34, n. 11, p. 1169-1178, 2025
- Este periódico é de acesso aberto
- Este artigo NÃO é de acesso aberto
-
ABNT
BARBOSA, Amanda Veiga et al. Does sex affect the efficacy, safety, and quality of life outcomes for patients using angiotensin receptor neprilysin inhibitor, soluble guanylate cyclase stimulators, and cardiac myosin activators in heart failure? a systematic review. Heart, Lung and Circulation, v. 34, n. 11, p. 1169-1178, 2025Tradução . . Disponível em: https://dx.doi.org/10.1016/j.hlc.2025.04.082. Acesso em: 09 fev. 2026. -
APA
Barbosa, A. V., Silva, L. C. A., Rotta, I., & Aguiar, P. M. (2025). Does sex affect the efficacy, safety, and quality of life outcomes for patients using angiotensin receptor neprilysin inhibitor, soluble guanylate cyclase stimulators, and cardiac myosin activators in heart failure? a systematic review. Heart, Lung and Circulation, 34( 11), 1169-1178. doi:10.1016/j.hlc.2025.04.082 -
NLM
Barbosa AV, Silva LCA, Rotta I, Aguiar PM. Does sex affect the efficacy, safety, and quality of life outcomes for patients using angiotensin receptor neprilysin inhibitor, soluble guanylate cyclase stimulators, and cardiac myosin activators in heart failure? a systematic review [Internet]. Heart, Lung and Circulation. 2025 ; 34( 11): 1169-1178.[citado 2026 fev. 09 ] Available from: https://dx.doi.org/10.1016/j.hlc.2025.04.082 -
Vancouver
Barbosa AV, Silva LCA, Rotta I, Aguiar PM. Does sex affect the efficacy, safety, and quality of life outcomes for patients using angiotensin receptor neprilysin inhibitor, soluble guanylate cyclase stimulators, and cardiac myosin activators in heart failure? a systematic review [Internet]. Heart, Lung and Circulation. 2025 ; 34( 11): 1169-1178.[citado 2026 fev. 09 ] Available from: https://dx.doi.org/10.1016/j.hlc.2025.04.082 - Economic evaluations on the use of aripiprazole for patients with schizophrenia: a systematic review
- Prevalence of depression and anxiety among pharmacy students: a systematic review
- Pharmacist interventions in schizophrenia and bipolar affective disorder: a systematic review and meta-analysis
- Use of medications by patients who are Deaf or Hard of Hearing: Reflections for the promotion of rational use
- Colaboração médico-farmacêutico no manejo de pacientes com diabetes mellitus tipo 2: expectativas e resultados
- Development of a value assessment framework for Health Technology Assessment in rare diseases drugs: insights from a Delphi study in Brazil
- Pharmacist participated medication review in different practice settings: service or intervention? an overview of systematic reviews
- Estomatite aftosa recorrente (afta)
- Hiperplasia prostática benigna
- Evaluation of mobile applications focused on the care of patients with anxiety disorders: a systematic review in app stores in Brazil
Informações sobre o DOI: 10.1016/j.hlc.2025.04.082 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
